このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

中等度から重度の活動性クローン病の小児参加者におけるウステキヌマブの研究 (UNITI Jr)

2026年7月2日 更新者:Janssen Research & Development, LLC

中等度から重度の活動性クローン病の小児患者を対象に、ウステキヌマブの無作為化二重盲検皮下投与維持療法に続く非盲検静脈内導入治療としてのウステキヌマブの有効性、安全性、および薬物動態に関する第 3 相試験

この研究の目的は、ウステキヌマブ投与の臨床的寛解の誘導 (グローバル) および臨床的寛解の維持 (米国) における有効性を評価することです。中等度から重度の活動性クローン病の小児参加者における安全性プロファイルとウステキヌマブ曝露(薬物動態[PK])を評価すること。

調査の概要

研究の種類

介入

入学 (実際)

101

段階

  • フェーズ 3

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • Delaware
      • Wilmington、Delaware、アメリカ、19803
        • Nemours DuPont Hospital for Children
    • Georgia
      • Atlanta、Georgia、アメリカ、30342
        • Children's Center for Digestive Health Care
    • Minnesota
      • Rochester、Minnesota、アメリカ、55905
        • Mayo Clinic
    • New Jersey
      • Morristown、New Jersey、アメリカ、07962
        • Morristown Memorial Hospital
    • North Carolina
      • Charlotte、North Carolina、アメリカ、28207
        • Levine Childrens at Atrium Health
    • Ohio
      • Cleveland、Ohio、アメリカ、44106
        • University Hospitals Cleveland Medical Center
    • Pennsylvania
      • Hershey、Pennsylvania、アメリカ、17033
        • Penn State Hershey Children's Hospital
    • Texas
      • Fort Worth、Texas、アメリカ、76104
        • Cook Childrens Medical Center
    • Virginia
      • Fairfax、Virginia、アメリカ、22031
        • Pediatric Specialists Of Virginia
      • Birmingham、イギリス、B4 6NH
        • Birmingham Children's Hospital
      • Bristol、イギリス、BS2 8BJ
        • University Hospitals Bristol and Weston NHS Foundation Trust
      • Cambridge、イギリス、CB2 0QQ
        • Cambridge University Hospitals NHS Foundation Trust
      • Edinburgh、イギリス、EH16 4TJ
        • Royal Hospital for Children and Young People
      • London、イギリス、E1 2AT
        • Royal London Hospital
      • Be’er Ya‘aqov、イスラエル、70300
        • Yitzhak Shamir Medical Center
      • Haifa、イスラエル、34362
        • Carmel Medical Center
      • Jerusalem、イスラエル、9103102
        • Shaare Zedek Medical Center
      • Petah Tikva、イスラエル、4920235
        • Schneider Children's Medical Center
      • Aachen、ドイツ、52074
        • Universitätsklinikum Aachen
      • Berlin、ドイツ、13353
        • Charite-Universitätsmedizin Berlin - Berlin
      • Essen、ドイツ、45147
        • Universitätsklinikum Essen
      • Hanover、ドイツ、30625
        • Medizinische Hochschule Hannover
      • Munich、ドイツ、80337
        • Dr. von Haunersches Kinderspital
      • Regensburg、ドイツ、93049
        • KUNO Klinik St. Hedwig
      • Ulm、ドイツ、89075
        • Universitätsklinikum Ulm
      • Budapest、ハンガリー、1083
        • Semmelweis Egyetem
      • Debrecen、ハンガリー、4032
        • Debreceni Egyetem Klinikai Kozpont
      • Miskolc、ハンガリー、3526
        • Borsod Abauj Zemplen Varmegyei Kozponti Korhaz es Egyetemi Oktato Korhaz
      • Nyíregyháza、ハンガリー、4400
        • Szabolcs Szatmár Bereg Vármegyei Oktatókórház
      • Szeged、ハンガリー、6720
        • Szegedi Tudományegyetem, Gyermekgyógyászati Klinika és Gyermekegészségügyi Centrum
      • Brussels、ベルギー、1200
        • Cliniques Universitaires Saint Luc
      • Brussels、ベルギー、1020
        • Universitair Kinderziekenhuis Koningin Fabiola
      • Ghent、ベルギー、9000
        • UZ Gent
      • Jette、ベルギー、1090
        • UZ Brussel
      • Leuven、ベルギー、3000
        • UZ Leuven
      • Gdansk、ポーランド、80 803
        • Szpital im. M. Kopernika
      • Krakow、ポーランド、30 663
        • Uniwersytecki Szpital Dzieciecy w Krakowie
      • Rzeszów、ポーランド、35-302
        • Korczowski Bartosz Gabinet Lekarski
      • Warsaw、ポーランド、04 501
        • WIP Warsaw IBD Point Profesor Kierkus
      • Warsaw、ポーランド、04 730
        • Instytut Pomnik Centrum Zdrowia Dziecka
      • Kazan'、ロシア、420138
        • Kazan State Medical University
      • Moscow、ロシア、119571
        • Russian National Research Medical University named after N.I.Pirogov
      • Nizhny Novgorod、ロシア、603950
        • Privolzhsky Research Medical University of Ministry of Health of Russian Federation
      • Yaroslavl、ロシア、150032
        • Yaroslavl Regional Children's Clinical Hospital
      • Bunkyō City、日本、113 8431
        • Juntendo University Hospital
      • Gunma、日本、371-0034
        • Gunma University Hospital
      • Ikoma、日本、630-0293
        • Kindai University Nara Hospital
      • Kurume、日本、830-0011
        • Kurume University Hospital
      • Saitama Shi、日本、330-8777
        • Saitama Childrens Medical Center
      • Sendai、日本、989-3126
        • Miyagi Children's Hospital
      • Setagaya Ku、日本、157 8535
        • National Center for Child Health and Development
      • Shimotsuke、日本、329-0498
        • Jichi Medical University Hospital
      • Tsu、日本、514 8507
        • Mie University Hospital

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

2年~17年 (子)

健康ボランティアの受け入れ

いいえ

説明

包含基準:

  • -過去の任意の時点で、内視鏡検査および組織学によって確認された、活動性大腸炎、回腸炎、または回腸炎を伴うクローン病または瘻孔性クローン病がある
  • -中等度から重度の活動性クローン病を持っている必要があります(ベースラインの小児クローン病活動指数[PCDAI]スコアによって定義される[>] 30より大きい); -潰瘍の存在として定義される活動性クローン病の証拠を伴う回腸結腸鏡検査を受けている(これは、クローン病の単純内視鏡スコア[SES-CD]スコアが[> =] 3以上である)この研究へのスクリーニング中。 回腸結腸内視鏡検査手順は、0 週目 (誘導期間) の研究介入の投与前の約 3 週間以内に行わなければなりません。 回腸結腸内視鏡検査を受けたが、別の理由で最初のスクリーニングに失敗した参加者の再スクリーニングの場合、場合によっては、第 0 週(誘導期)来院前の 3 か月以内に記録されたビデオ回腸結腸内視鏡検査を使用できます。スポンサーと相談。 狭窄または不十分な腸の準備のために潰瘍を評価できない場合は、代わりに次の基準の少なくとも 1 つを適用することができます。 [mg/L] スクリーニング時) または; -スクリーニング時に>= 250ミリグラム/キログラム[mg/kg]または>= 250マイクログラム/グラム[mcg/g]の糞便カルプロテクチン
  • -経腸栄養を受けている場合は、導入週0(I-0週)の少なくとも2週間前から安定したレジメンであった必要があります
  • -出産の可能性のある女性は、スクリーニング時および研究介入投与前のI-0週に、​​高感度の尿妊娠検査で陰性でなければなりません

除外基準:

  • -症候性狭窄または狭窄、短腸症候群、または手術が必要であると予想されるその他の症状などのクローン病の合併症があり、治療に対する反応を評価するためのPCDAIの使用を妨げる可能性がある、または評価する能力を混乱させる可能性があるウステキヌマブによる治療効果
  • -潜在的または活動的な肉芽腫性感染症、ヒストプラスマ症、またはコクシジオイデス症の病歴がある、またはスクリーニング前に非結核性マイコバクテリア感染症にかかったことがある
  • -リンパ腫を含むリンパ増殖性疾患の存在または病歴を含む悪性腫瘍の存在または病歴、または異常なサイズまたは位置のリンパ節腫脹などのリンパ増殖性疾患の可能性を示唆する徴候および症状(例、首の後三角、鎖骨下、滑車、または大動脈周囲領域)、および意義不明の単クローン性免疫グロブリン血症、または臨床的に重大な肝腫大または脾腫
  • -中等度または重度の進行性または制御不能な肝臓または腎不全の病歴がある;または重大な心臓、血管、肺、胃腸、内分泌、神経、血液、精神(自殺願望を含む)、または代謝障害
  • -治験ワクチンを含む治験介入を受けた、または侵襲的な治験医療機器を使用した 研究介入の計画された最初の投与の3か月前、または現在治験に登録されている;新型コロナウイルス病 2019 (COVID-19) の治験用ワクチンの受領は、自動除外基準ではありません

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:ダブル

武器と介入

参加者グループ / アーム
介入・治療
実験的:非盲検ウステキヌマブ静注(IV):導入期
すべての参加者は、体表面積(BSA)(ミリグラム/メートル平方[mg/m^2])または体重段階誘導用量(ミリグラム/キログラム)に基づいて、導入週0(I-0)にウステキヌマブの単回IV投与を受けます[mg/kg])。
ウステキヌマブは、導入期には静脈内に、維持期には皮下に投与されます。
実験的:ウステキヌマブ皮下投与 (SC) 8 週間ごと (q8w): 維持期間
参加者は、維持週(週M)-0、M-8、M-16、M-24でBSA(mg / m ^ 2)または体重段階誘導用量(mg / kg)に基づいてウステキヌマブq8wのSC投与を受ける、M 32、および M-40 と一致するプラセボを M-12 および M-36 週に投与して、盲検を維持します。
ウステキヌマブは、導入期には静脈内に、維持期には皮下に投与されます。
一致するプラセボは、SC 注射として投与されます。
実験的:ウステキヌマブ SC 12 週間ごと (q12w): 維持期間
参加者は、M-0、M-12、M-24、M-36 週に、BSA (mg/m^2) または体重段階誘導用量 (mg/kg) に基づくウステキヌマブ q12w の SC 投与を受けます。ブラインドを維持するために、M-8、M-16、M-32、および M-40 週。
ウステキヌマブは、導入期には静脈内に、維持期には皮下に投与されます。
一致するプラセボは、SC 注射として投与されます。

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Global Outcome Measure: Percentage of Participants With Clinical Remission at Induction Week 8 (Week I-8)
時間枠:Induction Week 8 (Week I-8)
Clinical remission was defined as a Pediatric Crohn's Disease Activity Index (PCDAI) score <=10. The 11-item PCDAI covered five general disease activity domains: symptom history scores (3 items: abdominal pain, stool frequency, and general well-being); laboratory scores (3 items: hematocrit [HCT], erythrocyte sedimentation rate [ESR], Albumin); growth scores (2 items: weight and height); physical examination scores (2 items: abdomen and perirectal disease); and extraintestinal manifestations. The category of severity for each index item is assigned a score: 0=normal;5=mild abnormality; 10= severe abnormality. For hematocrit and erythrocyte SR, the maximum score =5. For albumin level, the maximum score = 10. All items were summed to derive the total score. The total PCDAI score ranged from 0 to 100, with higher scores indicating greater disease activity.
Induction Week 8 (Week I-8)
US-specific Outcome Measure: Percentage of Participants With Clinical Remission at Maintenance Week 44
時間枠:Maintenance Week 44 (Study Week 52)
Clinical remission was defined as a Pediatric Crohn's Disease Activity Index (PCDAI) score <=10. The 11-item PCDAI covered five general disease activity domains: symptom history scores (3 items: abdominal pain, stool frequency, and general well-being); laboratory scores (3 items: HCT, ESR, Albumin); growth scores (2 items: weight and height); physical examination scores (2 items: abdomen and perirectal disease); and extraintestinal manifestations. The category of severity for each index item was assigned a score: 0=normal;5=mild abnormality; 10= severe abnormality. For hematocrit and erythrocyte SR, the maximum score= 5. For albumin level, the maximum score= 10. All items were summed to derive the total score. The total PCDAI score ranged from 0 to 100, with higher scores indicating greater disease activity.
Maintenance Week 44 (Study Week 52)
Global and US-specific Outcome Measures: Number of Participants With Treatment-emergent Adverse Events (TEAEs)
時間枠:Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
Number of participants with TEAEs were reported. An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE did not necessarily have a causal relationship with the intervention. TEAEs were defined as AEs occurring at or after the initial administration of the study intervention.
Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
Global and US-specific Outcome Measures: Number of Participants With Treatment-emergent Serious Adverse Events (TESAEs)
時間枠:Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
Number of participants with TESAEs was reported. An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE did not necessarily have a causal relationship with the intervention. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; or congenital anomaly. TESAEs were defined as any SAE occurring at or after the initial administration of the study intervention.
Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
Global and US-specific Outcome Measures: Number of Participants With AEs Leading to Discontinuation of Study Intervention
時間枠:Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 40 (Study Week 48)
Number of participants with AEs leading to discontinuation of study intervention were reported.
Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 40 (Study Week 48)
Global and US-specific Outcome Measures: Number of Participants With AEs of Special Interest (AESI)
時間枠:Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE did not necessarily have a causal relationship with the intervention. AESI were defined as any newly identified malignancy, or case of active TB, or opportunistic infection occurring after the first administration of study intervention.
Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
Global and US-specific Outcome Measures: Number of Participants With Abnormalities in Clinical Laboratory Parameters: Hematology
時間枠:Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
Number of participants with abnormalities in clinical laboratory parameters (hematology) were reported. It included hemoglobin (Hb). Grades 0-4 were based on the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), where Grade 0 was normal, Grade 1 was mild, Grade 2 was moderate, Grade 3 was severe or medically significant but not immediately life-threatening, and Grade 4 was life-threatening consequences. Higher grades showed more severe abnormalities. Only abnormalities where atleast one participant had data are reported. Inc = increased, Dec= decreased.
Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
Global and US-specific Outcome Measures: Number of Participants With Abnormalities in Clinical Laboratory Parameters: Chemistry
時間枠:Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
Number of participants with abnormalities in clinical laboratory parameters were reported. It included chemistry measures: alanine aminotransferase (ALT), aspartate aminotransferase (AST),blood bilirubin (BB). Grades 0-4 were based on NCI-CTCAE version 5.0, where Grade 0 was Normal, Grade 1 was mild, Grade 2 was moderate, Grade 3 was severe or medically significant but not immediately life-threatening, and Grade 4 was life-threatening consequences. Higher grades showed more severe abnormalities. Only abnormalities where at least one participant had data are reported. Inc = increased, Dec= decreased.
Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
Global and US-specific Outcome Measures: Number of Participants With Reactions Temporally Associated With Intravenous (IV) Infusion (Induction Period) and Subcutaneous (SC) Injection-Site Reactions (Maintenance Period)
時間枠:Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
Number of participants with reactions temporally associated with intravenous (IV) infusion (Induction Period) and subcutaneous (SC) Injection-Site Reactions (Maintenance Period) were reported.
Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
Global and US-specific Outcome Measures: Serum Ustekinumab Concentrations
時間枠:Induction Period: Week 0 (Pre-infusion), Week I-0 (1-hour post infusion), Week I-3, Week I-6, and Week I-8; Maintenance Period: Week M-4, Week M-8, Week M-12, Week M-16, Week M-24, Week M-32, Week M-36 and Week M-44
Serum ustekinumab concentrations were reported.
Induction Period: Week 0 (Pre-infusion), Week I-0 (1-hour post infusion), Week I-3, Week I-6, and Week I-8; Maintenance Period: Week M-4, Week M-8, Week M-12, Week M-16, Week M-24, Week M-32, Week M-36 and Week M-44

二次結果の測定

結果測定
メジャーの説明
時間枠
Global Outcome Measure: Percentage of Participants With Clinical Remission at Induction Week 6 as Assessed by Short Pediatric Crohn's Disease Activity Index (sPCDAI)
時間枠:Induction Week 6 (Week I-6)
Clinical remission was defined as a short Pediatric Crohn's Disease Activity Index (sPCDAI) score <=10. The sPCDAI was composed of six components: abdominal pain, stool frequency, patient general well-being, body weight, abdominal examination (abdominal mass and tenderness), and extraintestinal manifestations. Each component was assigned a score of 0, 5, 10, or 20, depending on the severity of findings, with higher scores indicating greater disease activity, while lower scores (closer to 0) reflected clinical remission or minimal disease activity. Individual component scores were summed to derive the total sPCDAI score, which ranged from 0 to 90. Higher score indicate greater severity. The sPCDAI score was calculated only when >=3 of the 6 components were available.
Induction Week 6 (Week I-6)
Global Outcome Measure: Percentage of Participants With Clinical Response at Induction Week 8
時間枠:Induction Week 8
Assessment of response in children with Crohn's disease was evaluated using the PCDAI. Clinical response was defined as a reduction from baseline of >=12.5 points in the PCDAI score, calculated by summing weighted scores from 11 items across five domains: symptom history (abdominal pain, stool frequency, and general well-being); laboratory scores (hematocrit, erythrocyte sedimentation rate, and albumin); growth scores (weight and height); physical examination scores (abdominal and perirectal disease); and extraintestinal manifestations. Each index item was assigned a severity score of 0 (normal), 5 (mild abnormality), or 10 (severe abnormality). For HCT and ESR, maximum score was 5, and for albumin level, maximum score was 10. The total PCDAI score ranged from 0 to 100, with higher scores indicating greater disease activity. Lower PCDAI scores reflected lower disease activity, with a resulting score of <=30 on the 0-100 scale.
Induction Week 8
Global and US-specific Outcome Measures: Percentage of Participants With Clinical Response at Induction Week 6 as Assessed by sPCDAI
時間枠:Induction Week 6
sPCDAI clinical response was defined as reduction from baseline in the sPCDAI score of >=10. The 6-item sPCDAI score ranges from 0 (no disease activity) to 90 (severe disease activity),calculated by summing weighted scores for abdominal pain, stool frequency, general well-being, body weight, abdominal exam, and extraintestinal manifestations. Each component was assigned a score of 0, 5, 10, or 20, depending on the severity of findings, with higher scores indicating greater disease activity, while lower scores (closer to 0) reflected minimal disease activity. Individual component scores were summed to derive the total sPCDAI score, which ranged from 0 to 90. Higher score indicate greater severity. The sPCDAI score was only calculated when >=3 of the 6 components were available.
Induction Week 6
Global Outcome Measure: Percentage of Participants With Endoscopic Response at Maintenance Week 8 as Assessed by Simplified Endoscopic Score-Crohn's Disease (SES-CD)
時間枠:Maintenance Period Week 8 (Study Week 16)
Endoscopic response was assessed using the Simplified Endoscopic Activity Score for Crohn's Disease (SES-CD), a validated endoscopic scoring system based on four components: size of ulcers, extent of ulcerated surface, extent of affected surface, and presence of narrowing. Each component was scored from 0 to 3 across five intestinal sections: ileum, right colon, transverse colon, left (descending and sigmoid) colon, and rectum. Component scores were summed across all sections to derive a total SES-CD score ranging from 0 to 56, with higher scores indicating greater endoscopic disease severity. Endoscopic response was defined as a >=50% reduction from baseline in SES-CD score or achievement of an SES-CD score <=2 in participants with a baseline SES-CD score >=3.
Maintenance Period Week 8 (Study Week 16)
Global Outcome Measure: Percentage of Participants With Clinical Response at Maintenance Week 8
時間枠:Maintenance Week 8 (Study Week 16)
Clinical response was defined as a reduction from baseline of >=12.5 points in PCDAI score, calculated by summing weighted scores from 11 items across five domains: symptom history(abdominal pain, stool frequency, and general well-being); laboratory scores (hematocrit, erythrocyte sedimentation rate, and albumin); growth scores(weight and height); physical examination scores(abdominal and perirectal disease); extraintestinal manifestations. Each index item was assigned a severity score of 0(normal), 5(mild abnormality), or 10(severe abnormality). For HCT and ESR, maximum score was 5, for albumin level, maximum score was 10. Total PCDAI score ranged from 0 to 100, with higher scores indicating greater disease activity. Lower PCDAI scores reflected lower disease activity, with resulting score of <=30 on 0-100 scale.
Maintenance Week 8 (Study Week 16)
Global and US-specific Outcome Measures: Percentage of Participants With Endoscopic Response at Maintenance Week 44 as Assessed by SES-CD
時間枠:Maintenance Week 44 (Study Week 52)
Endoscopic response was assessed using the Simplified Endoscopic Activity Score for Crohn's Disease (SES-CD), a validated endoscopic scoring system based on four components: size of ulcers, extent of ulcerated surface, extent of affected surface, and presence of narrowing. Each component was scored from 0 to 3 across five intestinal sections: ileum, right colon, transverse colon, left (descending and sigmoid) colon, and rectum. Component scores were summed across all sections to derive a total SES-CD score ranging from 0 to 56, with higher scores indicating greater endoscopic disease severity. Endoscopic response was defined as a >=50% reduction from baseline in SES-CD score or achievement of an SES-CD score <=2 in participants with a baseline SES-CD score >=3.
Maintenance Week 44 (Study Week 52)
US-specific Outcome Measure: Percentage of Participants With Clinical Response at Maintenance Week 44
時間枠:Maintenance Week 44 (Study Week 52)
Clinical response was defined as a reduction from baseline of >=12.5 points in PCDAI score, calculated by summing weighted scores from 11 items across five domains: symptom history(abdominal pain, stool frequency, and general well-being); laboratory scores (hematocrit, erythrocyte sedimentation rate, and albumin); growth scores(weight and height); physical examination scores(abdominal and perirectal disease); extraintestinal manifestations. Each index item was assigned a severity score of 0(normal), 5(mild abnormality), or 10(severe abnormality). For HCT and ESR, maximum score was 5, for albumin level, maximum score was 10. Total PCDAI score ranged from 0 to 100, with higher scores indicating greater disease activity. Lower PCDAI scores reflected lower disease activity, with resulting score of <=30 on 0-100 scale.
Maintenance Week 44 (Study Week 52)
US-specific Outcome Measure: Percentage of Participants With Corticosteroid-free Clinical Remission at Maintenance Week 44
時間枠:Maintenance Period Week 44 (Study Week 52)
Corticosteroid-free remission was defined as PCDAI score of <=10 points and not receiving corticosteroids for at least 90 days prior to Week M-44. The 11-item PCDAI covered five general disease activity domains: symptom history scores (3 items: abdominal pain, stool frequency; and general well-being); laboratory scores (3 items: HCT, ESR, Albumin); growth scores (2 items: weight and height), physical examination scores (2 items: abdomen and perirectal disease), and extraintestinal manifestations. The category of severity for each index item was assigned a score: 0=normal;5=mild abnormality; 10= severe abnormality. For hematocrit and erythrocyte SR, the maximum score= 5. For albumin level, the maximum score= 10. All items were summed to derive the total score. The total PCDAI score ranged from 0 to 100, with higher scores indicating greater disease activity.
Maintenance Period Week 44 (Study Week 52)
Global Outcome Measure: Percentage of Participants With Clinical Remission at Maintenance Week 44 Who Had Clinical Remission at Induction Week 8
時間枠:Maintenance Week 44 (Study Week 52)
Clinical remission was defined as Pediatric Crohn's Disease Activity Index (PCDAI) score <=10. The 11-item PCDAI covered five general disease activity domains: symptom history scores (3 items: abdominal pain, stool frequency; and general well-being); laboratory scores (3 items: HCT, ESR, Albumin); growth scores (2 items: weight and height), physical examination scores (2 items: abdomen and perirectal disease), and extraintestinal manifestations. The category of severity for each index item was assigned a score: 0=normal;5=mild abnormality; 10= severe abnormality. For hematocrit and erythrocyte SR, the maximum score= 5. For albumin level, the maximum score= 10. All items were summed to derive the total score. The total PCDAI score ranged from 0 to 100, with higher scores indicating greater disease activity.
Maintenance Week 44 (Study Week 52)

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

捜査官

  • スタディディレクター:Janssen Research & Development, LLC Clinical Trial、Janssen Research & Development, LLC

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2021年4月6日

一次修了 (実際)

2024年11月28日

研究の完了 (実際)

2025年3月3日

試験登録日

最初に提出

2020年12月14日

QC基準を満たした最初の提出物

2020年12月14日

最初の投稿 (実際)

2020年12月17日

学習記録の更新

投稿された最後の更新 (実際)

2026年7月30日

QC基準を満たした最後の更新が送信されました

2026年7月2日

最終確認日

2026年7月1日

詳しくは

本研究に関する用語

キーワード

その他の研究ID番号

  • CR108864
  • 2019-004225-24 (EudraCT番号)
  • CNTO1275CRD3004 (その他の識別子:Janssen Research & Development, LLC)
  • 2023-504978-38-00 (レジストリ識別子:EUCT number)

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

Johnson & Johnson の Janssen Pharmaceutical Companies のデータ共有ポリシーは、www.janssen.com/clinical-trials/transparency で入手できます。 このサイトに記載されているように、研究データへのアクセスのリクエストは、Yale Open Data Access (YODA) Project サイト (yoda.yale.edu) から送信できます。

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する